Craig Hallum Raises Harrow (NASDAQ:HROW) Price Target to $65.00

Harrow (NASDAQ:HROW) had its target price raised by Craig Hallum from $45.00 to $65.00 in a report released on Friday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, B. Riley reaffirmed a buy rating and issued a $50.00 price objective on shares of Harrow in a report on Thursday, August 29th.

Harrow Price Performance

Shares of NASDAQ HROW opened at $50.64 on Friday. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.60 and a quick ratio of 2.43. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -55.65 and a beta of 0.75. The stock’s 50-day moving average is $39.46 and its two-hundred day moving average is $24.79. Harrow has a 1-year low of $7.60 and a 1-year high of $51.81.

Harrow (NASDAQ:HROW) last issued its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.12. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. The business had revenue of $48.94 million for the quarter, compared to analyst estimates of $42.78 million. Analysts forecast that Harrow will post -0.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Harrow

Several hedge funds and other institutional investors have recently made changes to their positions in HROW. Vanguard Group Inc. lifted its position in shares of Harrow by 1.2% during the first quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock worth $24,208,000 after purchasing an additional 21,253 shares in the last quarter. Woodmont Investment Counsel LLC grew its stake in shares of Harrow by 73.3% during the first quarter. Woodmont Investment Counsel LLC now owns 211,579 shares of the company’s stock valued at $2,799,000 after acquiring an additional 89,510 shares in the last quarter. Private Capital Management LLC increased its position in shares of Harrow by 7.8% during the first quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock worth $39,854,000 after acquiring an additional 217,896 shares during the last quarter. Apis Capital Advisors LLC purchased a new position in Harrow in the second quarter valued at about $1,660,000. Finally, Bank of New York Mellon Corp grew its stake in Harrow by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 88,210 shares of the company’s stock valued at $1,843,000 after purchasing an additional 12,580 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.